Document:

<PAGE>   1

                                                                     EXHIBIT 4.5

THIS WARRANT AND ANY SECURITIES ACQUIRED UPON EXERCISE OF THIS WARRANT HAVE NOT
BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED
OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER SUCH ACT OR APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN
APPLICABLE EXEMPTION TO THE REGISTRATION REQUIREMENTS OF SUCH ACT AND SUCH LAWS.

                            NTN COMMUNICATIONS, INC.

                          COMMON STOCK PURCHASE WARRANT

No. W-                                                         November 14, 2000

                                                   Warrant to Purchase _________
                                                          Shares of Common Stock

                NTN COMMUNICATIONS, INC., a Delaware corporation (the
"Company"), for value received, hereby certifies that _________, or registered
assigns (the "Holder"), is entitled to purchase from the Company _________ (the
"Warrant Shares") duly authorized, validly issued, fully paid and nonassessable
shares of Common Stock, par value $.005 per share, of the Company (the "Common
Stock"), at a purchase price per share equal to the Purchase Price (as defined
below), at any time or from time to time on and after May 13, 2001 and prior to
5:00 P.M., New York City time, on May 13, 2004 (the "Expiration Date"), all
subject to the terms, conditions and adjustments set forth below in this
Warrant; provided, however, that the terms, conditions and adjustments under
this Warrant shall vest only upon the occurrence of a Vesting Event (as defined
below).

                This Warrant is one of the Common Stock Purchase Warrants
(collectively, the "Warrants", such term to include any such warrants issued in
substitution therefor) originally issued pursuant to the terms of the Securities
Purchase Agreement, dated as of November 13, 2000, by and among the Company and
the Buyers signatory thereto (the "Purchase Agreement"). Capitalized terms used
herein and not otherwise defined herein shall have the meanings assigned such
terms in the Purchase Agreement.

                1. DEFINITIONS. As used herein, unless the context otherwise
requires, the following terms shall have the meanings indicated:

<PAGE>   2

                "Additional Shares of Common Stock" shall mean, all shares
(including treasury shares) of Common Stock issued or sold (or, pursuant to
Section 3.3 or 3.4, deemed to be issued) by the Company after the date hereof,
whether or not subsequently reacquired or retired by the Company other than (i)
shares of Common Stock issued upon exercise of the Warrants, (ii) such number of
additional shares of Common Stock as may become issuable by exercise of the
Warrants by reason of adjustments required pursuant to the anti-dilution
provisions applicable to the Warrants, (iii) shares of Common Stock issued
pursuant to Approved Stock Plans and (iv) shares of Common Stock issued pursuant
to warrants issued and outstanding on November 13, 2000 and listed on Schedule
3(c) to the Purchase Agreement.

                "Anniversary Date" shall mean May 13 of each calendar year.

                "Approved Stock Plan" shall mean any contract, plan or agreement
which has been or shall be approved by the Board of Directors of the Company or
a committee of the Board of Directors, pursuant to which the Company's
securities may be issued to any employee, officer, director, consultant or other
service provider of the Company in an aggregate amount that does not exceed 110%
of the number of securities issuable as of November 13, 2000 pursuant to any
currently existing Approved Stock Plan.

                "Average Closing Bid Price" shall mean the average of the
Closing Bid Prices of the Common Stock for the twenty (20) days immediately
preceding the applicable date.

                "Average Market Price" shall mean the average of the Closing Bid
Prices of the Common Stock for the five (5) trading days immediately preceding
the applicable date.

                "Business Day" shall mean any day other than a Saturday or a
Sunday or a day on which commercial banking institutions in the City of New York
are authorized by law to be closed. Any reference to "days" (unless Business
Days are specified) shall mean calendar days.

                "Buy in Actual Damages" shall have the meaning assigned to it in
Section 2.6 of this Agreement.

                "Closing Bid Price" shall mean for any security as of any date,
the closing bid price of such security on the principal securities exchange or
trade market where such security is listed or traded as reported by Bloomberg,
L.P. ("Bloomberg"), or if the foregoing does not apply, the closing bid price of
such security in the over-the-counter market on the electronic bulletin board
for such security as reported by Bloomberg, or, if no closing bid price is
reported for such security by Bloomberg, the average of the bid prices of any
market makers for such security as reported in the "pink sheets" by the National
Quotation Bureau, Inc. If the Closing Bid Price cannot be calculated for such
security on such date, as set forth above, the Closing Bid Price of such
security shall be the fair market value as determined in good faith by an
investment banking firm selected

                                      -2-
<PAGE>   3

jointly by the Company and the Holder, with the fees and expenses of such
determination borne solely by the Company.

                "Commission" shall mean the Securities and Exchange Commission
or any successor agency having jurisdiction to enforce the Securities Act.

                "Common Stock" shall have the meaning assigned to it in the
introduction to this Warrant, such term to include any stock into which such
Common Stock shall have been changed or any stock resulting from any
reclassification of such Common Stock, and all other stock of any class or
classes (however designated) of the Company the holders of which have the right,
without limitation as to amount, either to all or to a share of the balance of
current dividends and liquidating dividends after the payment of dividends and
distributions on any shares entitled to preference.

                "Company" shall have the meaning assigned to it in the
introduction to this Warrant, such term to include any corporation or other
entity which shall succeed to or assume the obligations of the Company hereunder
in compliance with Section 4.

                "Convertible Securities" shall mean any evidences of
indebtedness, shares of stock (other than Common Stock) or other securities
directly or indirectly convertible into or exchangeable for Additional Shares of
Common Stock.

                "Current Market Price" shall mean, on any date specified herein,
the average of the daily Closing Bid Prices for the Common Stock during the 10
consecutive trading days commencing 15 trading days before such date, except
that, if on any such date the shares of Common Stock are not listed or admitted
for trading on any national securities exchange or quoted in the
over-the-counter market, the Current Market Price shall be the Fair Value on
such date.

                "Exchange Act" shall mean the Securities Exchange Act of 1934,
as amended from time to time, and the rules and regulations thereunder, or any
successor statute.

                "Expiration Date" shall have the meaning assigned to it in the
introduction to this Warrant.

                "Fair Value" shall mean, on any date specified herein (i) in the
case of cash, the dollar amount thereof, (ii) in the case of a security admitted
for trading on any national securities exchange or quoted in the
over-the-counter market, the Current Market Price, and (iii) in all other cases
as determined in good faith jointly by the Board of Directors of the Company and
the Holder; provided, however, that if such parties are unable to reach
agreement within a reasonable period of time, the Fair Value shall be determined
in good faith by an independent investment banking firm selected jointly by the
Company and the Holder or, if that selection cannot be made within ten days, by
an independent investment banking firm selected by the American Arbitration
Association in accordance with its rules, and provided further, that the Company
shall pay all of the fees and expenses of any third parties incurred in
connection with determining the Fair Value.

                                      -3-
<PAGE>   4

                "Options" shall mean any rights, options or warrants to
subscribe for, purchase or otherwise acquire either Additional Shares of Common
Stock or Convertible Securities.

                "Other Securities" shall mean any stock (other than Common
Stock) and other securities of the Company or any other Person (corporate or
otherwise) which the holders of the Warrants at any time shall be entitled to
receive, or shall have received, upon the exercise of the Warrants, in lieu of
or in addition to Common Stock, or which at any time shall be issuable or shall
have been issued in exchange for or in replacement of Common Stock or Other
Securities pursuant to Section 4 or otherwise.

                "Person" shall mean any individual, firm, partnership,
corporation, trust, joint venture, association, joint stock company, limited
liability company, unincorporated organization or any other entity or
organization, including a government or agency or political subdivision thereof,
and shall include any successor (by merger or otherwise) of such entity.

                "Purchase Agreement" shall have the meaning assigned to it in
the introduction to this Warrant.

                "Purchase Price" shall mean

<TABLE>
<CAPTION>
              Applicable Period                              Purchase Price
              -----------------                              --------------
<S>                                               <C>
(i)  for the period ending on November            the lesser of (a) $1.64125 and (b) the
12, 2001:                                         Average Closing Bid Price as of May
                                                  13, 2001

(ii)  from November 13, 2001 through May          the lesser of (a) the Purchase Price
12, 2002:                                         resulting from (i) above and (b) the
                                                  Average Closing Bid Price as of
                                                  November 13, 2001

(iii) from May 13, 2002 through November          the lesser of (a) the Purchase Price
12, 2002:                                         resulting from (ii) above and (b) the
                                                  Average Closing Bid Price as of May
                                                  13, 2002

(iv)  from November 13, 2002 through May          the lesser of (a) the Purchase Price
12, 2003:                                         resulting from (iii) above and (b) the
                                                  Average Closing Bid Price ending on
                                                  November 13, 2002

(v)  from May 13, 2003 through November           the lesser of (a) the Purchase Price
12, 2003:                                         resulting from (iv) above and (b) the
                                                  Average Closing Bid Price ending on
</TABLE>

                                      -4-
<PAGE>   5

<TABLE>
<S>                                               <C>
                                                  May 13, 2003

(vi)  from November 13, 2003 through May          the lesser of (a) the Purchase Price
12, 2004:                                         resulting from (v) above and (b) the
                                                  Average Closing Bid Price ending on
                                                  November 13, 2003
</TABLE>

                provided, however, that such amount shall be subject to
adjustment and readjustment from time to time as provided in Section 3, and, as
so adjusted or readjusted, shall remain in effect until a further adjustment or
readjustment thereof is required by Section 3.

                "Registration Rights Agreement" shall mean the Registration
Agreement dated as of November 13, 2000, substantially in the form of Exhibit C
to the Purchase Agreement.

                "Rights" shall have the meaning assigned to it in Section 3.10.

                "Securities Act" shall mean the Securities Act of 1933, as
amended from time to time, and the rules and regulations thereunder, or any
successor statute.

                "Vesting Event" shall mean the failure of the Company to receive
from Persons other than the Holder or any of its affiliates, in the aggregate,
U.S.$5.0 million from the sale of Common Stock of the Company prior to 5:00
P.M., New York City time, on May 12, 2001 (the "Five Million Threshold");
provided, however, that any capital or funds received from Persons other than
the Holder or any of its affiliates on the Closing Date shall be counted towards
the satisfaction of the Five Million Threshold; and provided, further, that any
purchase of the equity interest of BUZZTIME, Inc., a subsidiary of the Company,
shall also be counted towards the satisfaction of the Five Million Threshold.

                "Warrants" shall have the meaning assigned to it in the
introduction to this Warrant.

                2. EXERCISE OF WARRANT.

                2.1. Manner of Exercise; Payment of the Purchase Price. (a) This
Warrant may be exercised by the Holder, in whole or in part, at any time or from
time to time on and after May 13, 2001 (and only if the Vesting Event has
occurred) and prior to the Expiration Date, by surrendering to the Company at
its principal office (or such other office or agency of the Company as the
Company may designate in a written notice to the Holder) this Warrant, together
with the form of Election to Purchase Shares attached hereto as Exhibit A (or a
reasonable facsimile thereof) duly executed by the Holder and accompanied by
payment of the Purchase Price as described below for the number of shares of
Common Stock specified in such form.

                (b) Payment of the Purchase Price may be made as follows (or by
any combination of the following): (i) in United States currency by cash or
delivery of a

                                      -5-
<PAGE>   6

certified check or bank draft payable to the order of the Company or by wire
transfer to the account of the Company, (ii) by cancellation of such number of
the shares of Common Stock otherwise issuable to the Holder upon such exercise
as shall be specified in such Election to Purchase Shares, such that the excess
of the Current Market Price of such specified number of shares on the date of
exercise over the portion of the Purchase Price attributable to such shares
shall equal the Purchase Price attributable to the shares of Common Stock to be
issued upon such exercise, in which case upon delivery of such notice such
amount shall be deemed to have been paid to the Company and the number of shares
issuable upon such exercise shall be reduced by such specified number, or (iii)
by surrender to the Company for cancellation, certificates representing shares
of Common Stock of the Company owned by the Holder (properly endorsed for
transfer in blank) having a Current Market Price on the date of Warrant exercise
equal to the Purchase Price.

                2.2. When Exercise Effective. Each exercise of this Warrant
shall be deemed to have been effected immediately prior to the close of business
on the Business Day on which this Warrant shall have been surrendered to, and
the Purchase Price shall have been received by, the Company as provided in
Section 2.1, and at such time the Person or Persons in whose name or names any
certificate or certificates for shares of Common Stock (or Other Securities)
shall be issuable upon such exercise as provided in Section 2.3 shall be deemed
to have become the holder or holders of record thereof for all purposes.

                2.3. Delivery of Stock Certificates, etc.; Charges, Taxes and
Expenses. Subject to Section 2.5 (a) as soon as practicable after each exercise
of this Warrant, in whole or in part, and in any event within three (3) Business
Days thereafter, the Company shall cause to be issued in such denominations as
may be requested by Holder in the Election to Purchase Shares, in the name of
and delivered to the Holder or, subject the Purchase Agreement, as the Holder
may direct,

                (i) a certificate or certificates, or, if then permissible under
        the Securities Act, at a Holder's request to electronically issue such
        shares (e.g., through DWAC or DTC), an electronic issuance for the
        number of shares of Common Stock (or Other Securities) to which the
        Holder shall be entitled upon such exercise plus, in lieu of issuance of
        any fractional share to which the Holder would otherwise be entitled, if
        any, a certified check for the amount of cash equal to the same fraction
        multiplied by the Current Market Price per share on the date of Warrant
        exercise, provided, however, that in the event sufficient funds are not
        legally available for the payment of such amount, the number of shares
        of Common Stock for which such certificate(s) represents shall be
        rounded up to the nearest whole number, and

                (ii) in case such exercise is for less than all of the shares of
        Common Stock purchasable under this Warrant, a new Warrant or Warrants
        of like tenor, for the balance of the shares of Common Stock purchasable
        hereunder.

                                      -6-
<PAGE>   7

                (b) Issuance of certificates for shares of Common Stock upon the
exercise of this Warrant shall be made without charge to the Holder hereof for
any issue or transfer tax or other incidental expense, in respect of the
issuance of such certificates, all of which such taxes and expenses shall be
paid by the Company.

                2.4. Company to Reaffirm Obligations. The Company shall, at the
time of each exercise of this Warrant, upon the request of the Holder hereof,
acknowledge in writing its continuing obligation to afford to such Holder all
rights to which such Holder shall continue to be entitled after such exercise in
accordance with the terms of this Warrant, provided that if the Holder of this
Warrant shall fail to make any such request, such failure shall not affect the
continuing obligation of the Company to afford such rights to the Holder.

                2.5. Exercise Disputes. In the case of any dispute with respect
to the number of shares to be issued upon exercise of this Warrant, the Company
shall promptly issue such number of shares of Common Stock that is not disputed
and shall submit the disputed determinations or arithmetic calculations to the
Holder via facsimile within two (2) Business Days of receipt of the Holder's
Election to Purchase Shares. If the Holder and the Company are unable to agree
as to the determination of the Purchase Price within two (2) Business Days of
such disputed determination or arithmetic calculation being submitted to the
Holder, then the Company shall in accordance with this Section, submit via
facsimile the disputed determination to an independent reputable accounting firm
of national standing, selected jointly by the Company and the Holder. The
Company shall cause such accounting firm to perform the determinations or
calculations and notify the Company and the Holder of the results within
forty-eight (48) hours from the time it receives the disputed determinations of
calculations. Such accounting firm's determination shall be binding upon all
parties absent manifest error. The Company shall then on the next Business Day
issue certificate(s) representing the appropriate number of shares of Common
Stock in accordance with such accounting firm's determination and this Section.
All fees and expenses of such determination and calculation shall be borne by
the Company.

                2.6. Failure to Deliver Common Stock If, at any time, the Holder
of this Warrant submits this Warrant, an Election to Purchase Shares and payment
to the Company of the Purchase Price for each of the shares of Common Stock
specified in the Election to Purchase Shares in accordance with Section 2.1
above, and the Company, for any reason, fails to deliver, on or prior to the
last possible date which the Company could have issued such Common Stock to the
Holder without violating this Section 2, the number of shares of Common Stock
for which the Holder is entitled upon such exercise, the Company shall pay
damages to the Holder equal to the greater of (a) actual damages incurred by the
Holder as a result of the Holder's needing to "buy in" shares of Common Stock to
the extent necessary to satisfy its securities delivery requirements ("Buy In
Actual Damages") and (b) if the Company fails to deliver such certificates
within five days after the last possible date on which the Company could have
issued such Common Stock to the Holder without violating this Section 2, on each
date such exercise is not timely effected in an amount equal to 1% of the
product of (i) the number of shares of Common Stock not issued to the Holder on
a timely basis and to which the Holder is

                                      -7-
<PAGE>   8

entitled and (ii) the Closing Bid Price of the Common Stock on the last possible
date which the Company could have issued such Common Stock to the Holder without
violating this Section 2.

                3. ADJUSTMENT OF COMMON STOCK ISSUABLE UPON EXERCISE.

                3.1. Adjustment of Number of Shares.

                        Upon each adjustment of the Purchase Price as a result
of the calculations made in this Section 3, this Warrant shall thereafter
evidence the right to receive, at the adjusted Purchase Price, that number of
shares of Common Stock (calculated to the nearest one-hundredth) obtained by
dividing (i) the product of the aggregate number of shares covered by this
Warrant immediately prior to such adjustment and the Purchase Price in effect
immediately prior to such adjustment of the Purchase Price by (ii) the Purchase
Price in effect immediately after such adjustment of the Purchase Price.

                3.2. Adjustment of Purchase Price.

                3.2.1. Issuance of Additional Shares of Common Stock. In case
the Company at any time or from time to time after the date hereof shall issue
or sell Additional Shares of Common Stock (including Additional Shares of Common
Stock deemed to be issued pursuant to Section 3.3 or 3.4 but excluding
Additional Shares of Common Stock purchasable upon exercise of Rights referred
to in Section 3.10), without consideration or for a consideration per share less
than the Average Market Price as in effect immediately prior to such issue or
sale, then, and in each such case, subject to Section 3.8, the Purchase Price
shall be reduced, concurrently with such issue or sale, to a price (calculated
to the nearest .001 of a cent) determined by multiplying such Purchase Price by
a fraction

                (a) the numerator of which shall be the sum of (i) the number of
        shares of Common Stock outstanding immediately prior to such issue or
        sale and (ii) the number of shares of Common Stock which the gross
        consideration received by the Company for the total number of such
        Additional Shares of Common Stock so issued or sold would purchase at
        such Current Market Price, and

                (b) the denominator of which shall be the number of shares of
        Common Stock outstanding immediately after such issue or sale, provided
        that, for the purposes of this Section 3.2.1, (x) immediately after any
        Additional Shares of Common Stock are deemed to have been issued
        pursuant to Section 3.3 or 3.4, such Additional Shares shall be deemed
        to be outstanding, and (y) treasury shares shall not be deemed to be
        outstanding.

                3.2.2. Extraordinary Dividends and Distributions. In case the
Company at any time or from time to time after the date hereof shall declare,
order, pay or make a dividend or other distribution (including, without
limitation, any distribution of other or additional stock or other securities or
property or Options by way of dividend or spin-off,

                                      -8-
<PAGE>   9

reclassification, recapitalization or similar corporate rearrangement) on the
Common Stock, then, in each such case, subject to Section 3.8, the Purchase
Price in effect immediately prior to the close of business on the record date
fixed for the determination of holders of any class of securities entitled to
receive such dividend or distribution shall be reduced, effective as of the
close of business on such record date, to a price determined by multiplying such
Purchase Price by a fraction

                (x) the numerator of which shall be the Current Market Price in
        effect on such record date or, if the Common Stock trades on an
        ex-dividend basis, on the date prior to the commencement of ex-dividend
        trading, less the Fair Value of such dividend or distribution applicable
        to one share of Common Stock, and

                (y) the denominator of which shall be such Current Market Price.

                3.3. Treatment of Options and Convertible Securities. In case
the Company at any time or from time to time after the date hereof shall issue,
sell, grant or assume, or shall fix a record date for the determination of
holders of any class of securities of the Company entitled to receive, any
Options or Convertible Securities (whether or not the rights thereunder are
immediately exercisable) then, and in each such case, the maximum number of
Additional Shares of Common Stock (as set forth in the instrument relating
thereto, without regard to any provisions contained therein for a subsequent
adjustment of such number) issuable upon the exercise of such Options or, in the
case of Convertible Securities and Options therefor, the conversion or exchange
of such Convertible Securities, shall be deemed to be Additional Shares of
Common Stock issued as of the time of such issue, sale, grant or assumption or,
in case such a record date shall have been fixed, as of the close of business on
such record date (or, if the Common Stock trades on an ex-dividend basis, on the
date prior to the commencement of ex-dividend trading), provided that such
Additional Shares of Common Stock shall not be deemed to have been issued unless
(i) the consideration per share (determined pursuant to Section 3.5) of such
shares would be less than the Average Market Price as in effect on the date of
and immediately prior to such issue, sale, grant or assumption or immediately
prior to the close of business on such record date (or, if the Common Stock
trades on an ex-dividend basis, on the date prior to the commencement of
ex-dividend trading), as the case may be and (ii) such Additional Shares of
Common Stock are not purchasable pursuant to Rights referred to in Section 3.10,
and provided, further, that

                (a) whether or not the Additional Shares of Common Stock
        underlying such Options or Convertible Securities are deemed to be
        issued, no further adjustment of the Purchase Price shall be made upon
        the subsequent issue or sale of Convertible Securities or shares of
        Common Stock upon the exercise of such Options or the conversion or
        exchange of such Convertible Securities;

                (b) if such Options or Convertible Securities by their terms
        provide, with the passage of time or otherwise, for any increase in the
        consideration payable to the Company, or decrease in the number of
        Additional Shares of Common Stock issuable, upon the exercise,
        conversion or exchange thereof (by change of rate or otherwise), the
        Purchase Price computed upon the original issue,

                                      -9-
<PAGE>   10

        sale, grant or assumption thereof (or upon the occurrence of the record
        date, or date prior to the commencement of ex-dividend trading, as the
        case may be, with respect thereto), and any subsequent adjustments based
        thereon, shall, upon any such increase or decrease becoming effective,
        be recomputed to reflect such increase or decrease insofar as it affects
        such Options, or the rights of conversion or exchange under such
        Convertible Securities, which are outstanding at such time;

                (c) upon the expiration or termination (or purchase by the
        Company and cancellation or retirement) of any such Options which shall
        not have been exercised or the expiration of any rights of conversion or
        exchange under any such Convertible Securities which (or purchase by the
        Company and cancellation or retirement of any such Convertible
        Securities the rights of conversion or exchange under which) shall not
        have been exercised, the Purchase Price computed upon the original
        issue, sale, grant or assumption thereof (or upon the occurrence of the
        record date, or date prior to the commencement of ex-dividend trading,
        as the case may be, with respect thereto), and any subsequent
        adjustments based thereon, shall, upon such expiration (or such
        cancellation or retirement, as the case may be), be recomputed as if:

                        (i) in the case of Options for Common Stock or
                Convertible Securities, the only Additional Shares of Common
                Stock issued or sold were the Additional Shares of Common Stock,
                if any, actually issued or sold upon the exercise of such
                Options or the conversion or exchange of such Convertible
                Securities and the consideration received therefor was the
                consideration actually received by the Company for the issue,
                sale, grant or assumption of all such Options, whether or not
                exercised, plus the consideration actually received by the
                Company upon such exercise, or for the issue or sale of all such
                Convertible Securities which were actually converted or
                exchanged, plus the additional consideration, if any, actually
                received by the Company upon such conversion or exchange, and

                        (ii) in the case of Options for Convertible Securities,
                only the Convertible Securities, if any, actually issued or sold
                upon the exercise of such Options were issued at the time of the
                issue or sale, grant or assumption of such Options, and the
                consideration received by the Company for the Additional Shares
                of Common Stock deemed to have then been issued was the
                consideration actually received by the Company for the issue,
                sale, grant or assumption of all such Options, whether or not
                exercised, plus the consideration deemed to have been received
                by the Company (pursuant to Section 3.5) upon the issue or sale
                of such Convertible Securities with respect to which such
                Options were actually exercised;

                (d) no readjustment pursuant to subdivision (b) or (c) above
        shall have the effect of increasing the Purchase Price by an amount in
        excess of the amount

                                      -10-
<PAGE>   11

        of the adjustment thereof originally made in respect of the issue, sale,
        grant or assumption of such Options or Convertible Securities; and

                (e) in the case of any such Options which expire by their terms
        not more than 30 days after the date of issue, sale, grant or assumption
        thereof, no adjustment of the Purchase Price shall be made until the
        expiration or exercise of all such Options, whereupon such adjustment
        shall be made in the manner provided in subdivision (c) above.

                3.4. Treatment of Stock Dividends, Stock Splits, etc. In case
the Company at any time or from time to time after the date hereof shall declare
or pay any dividend on the Common Stock payable in Common Stock, or shall effect
a subdivision of the outstanding shares of Common Stock into a greater number of
shares of Common Stock (by reclassification or otherwise than by payment of a
dividend in Common Stock), then, and in each such case, Additional Shares of
Common Stock shall be deemed to have been issued (a) in the case of any such
dividend, immediately after the close of business on the record date for the
determination of holders of any class of securities entitled to receive such
dividend, or (b) in the case of any such subdivision, at the close of business
on the day immediately prior to the day upon which such corporate action becomes
effective.

                3.5. Computation of Consideration. For the purposes of this
Section 3,

                (a) the consideration for the issue or sale of any Additional
        Shares of Common Stock shall, irrespective of the accounting treatment
        of such consideration,

                        (i) insofar as it consists of cash, be computed at the
                amount of cash received by the Company, without deducting any
                expenses paid or incurred by the Company or any commissions or
                compensations paid or concessions or discounts allowed to
                underwriters, dealers or others performing similar services in
                connection with such issue or sale,

                        (ii) insofar as it consists of property (including
                securities) other than cash, be computed at the Fair Value
                thereof at the time of such issue or sale, and

                        (iii) in case Additional Shares of Common Stock are
                issued or sold together with other stock or securities or other
                assets of the Company for a consideration which covers both, be
                the portion of such consideration so received, computed as
                provided in clauses (i) and (ii) above, allocable to such
                Additional Shares of Common Stock, such allocation to be
                determined in the same manner that the Fair Value of property
                not consisting of cash or securities is to be determined as
                provided in the definition of 'Fair Value' herein;

                                      -11-
<PAGE>   12

                (b) Additional Shares of Common Stock deemed to have been issued
        pursuant to Section 3.3, relating to Options and Convertible Securities,
        shall be deemed to have been issued for a consideration per share
        determined by dividing

                        (i) the total amount, if any, received and receivable by
                the Company as consideration for the issue, sale, grant or
                assumption of the Options or Convertible Securities in question,
                plus the minimum aggregate amount of additional consideration
                (as set forth in the instruments relating thereto, without
                regard to any provision contained therein for a subsequent
                adjustment of such consideration to protect against dilution)
                payable to the Company upon the exercise in full of such Options
                or the conversion or exchange of such Convertible Securities or,
                in the case of Options for Convertible Securities, the exercise
                of such Options for Convertible Securities and the conversion or
                exchange of such Convertible Securities, in each case computing
                such consideration as provided in the foregoing subdivision (a),

                by

                        (ii) the maximum number of shares of Common Stock (as
                set forth in the instruments relating thereto, without regard to
                any provision contained therein for a subsequent adjustment of
                such number to protect against dilution) issuable upon the
                exercise of such Options or the conversion or exchange of such
                Convertible Securities; and

                (c) Additional Shares of Common Stock deemed to have been issued
        pursuant to Section 3.4, relating to stock dividends, stock splits,
        etc., shall be deemed to have been issued for no consideration.

                3.6. Adjustments for Combinations, etc. In case the outstanding
shares of Common Stock shall be combined or consolidated, by reclassification or
otherwise, into a lesser number of shares of Common Stock, the Purchase Price in
effect immediately prior to such combination or consolidation shall,
concurrently with the effectiveness of such combination or consolidation, be
proportionately increased.

                3.7. Dilution in Case of Other Securities. In case any Other
Securities shall be issued or sold or shall become subject to issue or sale upon
the conversion or exchange of any stock (or Other Securities) of the Company (or
any issuer of Other Securities or any other Person referred to in Section 4) or
to subscription, purchase or other acquisition pursuant to any Options issued or
granted by the Company (or any such other issuer or Person) for a consideration
such as to dilute, on a basis consistent with the standards established in the
other provisions of this Section 3, the purchase rights granted by this Warrant,
then, and in each such case, the computations, adjustments and readjustments
provided for in this Section 3 with respect to the Purchase Price and the number
of shares purchasable upon Warrant exercise shall be made as nearly as possible
in the manner so provided and applied to determine the amount of Other
Securities from

                                      -12-
<PAGE>   13

time to time receivable upon the exercise of the Warrants, so as to protect the
holders of the Warrants against the effect of such dilution.

                3.8. De Minimis Adjustments. If the amount of any adjustment of
the Purchase Price per share required pursuant to this Section 3 would be less
than $.01, such amount shall be carried forward and adjustment with respect
thereto made at the time of and together with any subsequent adjustment which,
together with such amount and any other amount or amounts so carried forward,
shall aggregate a change in the Purchase Price of at least $.01 per share. All
calculations under this Warrant shall be made to the nearest .001 of a cent or
to the nearest one-hundredth of a share, as the case may be.

                3.9. Abandoned Dividend or Distribution. If the Company shall
take a record of the holders of its Common Stock for the purpose of entitling
them to receive a dividend or other distribution (which results in an adjustment
to the Purchase Price under the terms of this Warrant) and shall, thereafter,
and before such dividend or distribution is paid or delivered to stockholders
entitled thereto, legally abandon its plan to pay or deliver such dividend or
distribution, then any adjustment made to the Purchase Price and number of
shares of Common Stock purchasable upon Warrant exercise by reason of the taking
of such record shall be reversed, and any subsequent adjustments, based thereon,
shall be recomputed.

                3.10. Shareholder Rights Plan. Notwithstanding the foregoing, in
the event that the Company shall distribute "poison pill" rights pursuant to a
"poison pill" shareholder rights plan (the "Rights"), the Company shall, in lieu
of making any adjustment pursuant to Section 3.2.1 or Section 3.2.2 hereof, make
proper provision so that each Holder who exercises a Warrant after the record
date for such distribution and prior to the expiration or redemption of the
Rights shall be entitled to receive upon such exercise, in addition to the
shares of Common Stock issuable upon such exercise, a number of Rights to be
determined as follows: (i) if such exercise occurs on or prior to the date for
the distribution to the holders of Rights of separate certificates evidencing
such Rights (the "Distribution Date"), the same number of Rights to which a
holder of a number of shares of Common Stock equal to the number of shares of
Common Stock issuable upon such exercise at the time of such exercise would be
entitled in accordance with the terms and provisions of and applicable to the
Rights; and (ii) if such exercise occurs after the Distribution Date, the same
number of Rights to which a holder of the number of shares into which the
Warrant so exercised was exercisable immediately prior to the Distribution Date
would have been entitled on the Distribution Date in accordance with the terms
and provisions of and applicable to the Rights, and in each case subject to the
terms and conditions of the Rights.

                4. CONSOLIDATION, MERGER, ETC.

                4.1. Adjustments for Consolidation, Merger, Sale of Assets,
Reorganization, etc. In case the Company after the date hereof (a) shall
consolidate with or merge into any other Person and shall not be the continuing
or surviving corporation of such consolidation or merger, or (b) shall permit
any other Person to consolidate with or merge into the Company and the Company
shall be the continuing or surviving Person

                                      -13-
<PAGE>   14

but, in connection with such consolidation or merger, the Common Stock or Other
Securities shall be changed into or exchanged for stock or other securities of
any other Person or cash or any other property, or (c) shall transfer all or
substantially all of its properties or assets to any other Person, or (d) shall
effect a capital reorganization or reclassification of the Common Stock or Other
Securities (other than a capital reorganization or reclassification resulting in
the issue of Additional Shares of Common Stock for which adjustment in the
Purchase Price is provided in Section 3.2.1 or 3.2.2), then, and in the case of
each such transaction, proper provision shall be made so that, upon the basis
and the terms and in the manner provided in this Warrant, the Holder of this
Warrant, upon the exercise hereof at any time after the consummation of such
transaction shall be entitled to receive (at the aggregate Purchase Price in
effect at the time of such consummation for all Common Stock or Other Securities
issuable upon such exercise immediately prior to such consummation), in lieu of
the Common Stock or Other Securities issuable upon such exercise prior to such
consummation, the amount of securities, cash or other property to which such
Holder would actually have been entitled as a stockholder upon such consummation
if such Holder had exercised this Warrant immediately prior thereto, subject to
adjustments (subsequent to such consummation) as nearly equivalent as possible
to the adjustments provided for in Sections 3 through 5.

                4.2. Assumption of Obligations. Notwithstanding anything
contained in the Warrants or in the Purchase Agreement to the contrary, the
Company shall not effect any of the transactions described in clauses (a)
through (d) of Section 4.1 unless, prior to the consummation thereof, each
Person (other than the Company) which may be required to deliver any stock,
securities, cash or property upon the exercise of this Warrant as provided
herein shall assume, by written instrument delivered to, and reasonably
satisfactory to, the Holder of this Warrant, (a) the obligations of the Company
under this Warrant (and if the Company shall survive the consummation of such
transaction, such assumption shall be in addition to, and shall not release the
Company from, any continuing obligations of the Company under this Warrant), (b)
the obligations of the Company under the Purchase Agreement and the Registration
Rights Agreement and (c) the obligation to deliver to the Holder such shares of
stock, securities, cash or property as, in accordance with the foregoing
provisions of this Section 4, the Holder may be entitled to receive. Nothing in
this Section 4 shall be deemed to authorize the Company to enter into any
transaction not otherwise permitted by the Purchase Agreement.

                5. OTHER DILUTIVE EVENTS. In case any event shall occur as to
which the provisions of Section 3 or Section 4 hereof are not strictly
applicable or if strictly applicable would not fairly protect the purchase
rights of the Holder in accordance with the essential intent and principles of
such Sections, then, in each such case, the Board of Directors of the Company
shall make an adjustment in the application of such provisions, in accordance
with such essential intent and principles, so as to preserve, without dilution,
the purchase rights represented by this Warrant.

                6. NO DILUTION OR IMPAIRMENT. The Company shall not, by
amendment of its certificate of incorporation or through any consolidation,
merger, reorganization, transfer of assets, dissolution, issue or sale of
securities or any other

                                      -14-
<PAGE>   15

voluntary action, avoid or seek to avoid the observance or performance of any of
the terms of this Warrant, but will at all times in good faith assist in the
carrying out of all such terms and in the taking of all such action as may be
reasonably necessary or appropriate in order to protect the rights of the Holder
of this Warrant against dilution or other impairment. Without limiting the
generality of the foregoing, the Company (a) shall not permit the par value of
any shares of stock receivable upon the exercise of this Warrant to exceed the
amount payable therefor upon such exercise, (b) shall take all such action as
may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable shares of stock, free from all taxes,
liens, security interests, encumbrances, preemptive rights and charges on the
exercise of the Warrants from time to time outstanding, (c) shall not take any
action which results in any adjustment of the Purchase Price if the total number
of shares of Common Stock (or Other Securities) issuable after the action upon
the exercise of all of the Warrants would exceed the total number of shares of
Common Stock (or Other Securities) then authorized by the Company's certificate
of incorporation and available for the purpose of issue upon such exercise, and
(d) shall not issue any capital stock of any class which is preferred as to
dividends or as to the distribution of assets upon voluntary or involuntary
dissolution, liquidation or winding-up, unless the rights of the holders thereof
shall be limited to a fixed sum or percentage of par value or a sum determined
by reference to a formula based on a published index of interest rates, an
interest rate publicly announced by a financial institution or a similar
indicator of interest rates in respect of participation in dividends and to a
fixed sum or percentage of par value in any such distribution of assets.

                7. CERTIFICATE AS TO ADJUSTMENTS. In each case of any adjustment
or readjustment in the shares of Common Stock (or Other Securities) issuable
upon the exercise of this Warrant, the Company at its expense shall promptly
compute such adjustment or readjustment in accordance with the terms of this
Warrant and prepare a certificate, signed by the Chairman of the Board,
President or one of the Vice Presidents of the Company, and by the Chief
Financial Officer, the Treasurer or one of the Assistant Treasurers of the
Company, setting forth such adjustment or readjustment and showing in reasonable
detail the method of calculation thereof and the facts upon which such
adjustment or readjustment is based, including a statement of (a) the
consideration received or to be received by the Company for any Additional
Shares of Common Stock issued or sold or deemed to have been issued, (b) the
number of shares of Common Stock outstanding or deemed to be outstanding, and
(c) the Purchase Price in effect immediately prior to such issue or sale and as
adjusted and readjusted (if required by Section 3) on account thereof. The
Company shall forthwith mail a copy of each such certificate to each holder of a
Warrant and shall, upon the written request at any time of any holder of a
Warrant, furnish to such holder a like certificate. The Company shall also keep
copies of all such certificates at its principal office and shall cause the same
to be available for inspection at such office during normal business hours by
any holder of a Warrant or any prospective purchaser of a Warrant designated by
the holder thereof. The Company shall, upon the request in writing of the Holder
(at the Company's expense), retain independent public accountants of recognized
national standing selected by the Board of Directors of the Company to make any
computation required in connection with adjustments under this Warrant, and a
certificate signed by such firm shall be conclusive

                                      -15-
<PAGE>   16

evidence of the correctness of such adjustment, which shall be binding on the
Holder and the Company.

                8. NOTICES OF CORPORATE ACTION. In the event of:

                (a) any taking by the Company of a record of the holders of any
        class of securities for the purpose of determining the holders thereof
        who are entitled to receive any dividend or other distribution, or any
        right to subscribe for, purchase or otherwise acquire any shares of
        stock of any class or any other securities or property, or to receive
        any other right, or

                (b) any capital reorganization of the Company, any
        reclassification or recapitalization of the capital stock of the
        Company, any consolidation or merger involving the Company and any other
        Person, any transaction or series of transactions in which more than 50%
        of the voting securities of the Company are transferred to another
        Person, or any transfer, sale or other disposition of all or
        substantially all the assets of the Company to any other Person, or

                (c) any voluntary or involuntary dissolution, liquidation or
        winding-up of the Company,

the Company shall mail to each holder of a Warrant a notice specifying (i) the
date or expected date on which any such record is to be taken for the purpose of
such dividend, distribution or right, and the amount and character of such
dividend, distribution or right, and (ii) the date or expected date on which any
such reorganization, reclassification, recapitalization, consolidation, merger,
transfer, sale, disposition, dissolution, liquidation or winding-up is to take
place and the time, if any such time is to be fixed, as of which the holders of
record of Common Stock (or Other Securities) shall be entitled to exchange their
shares of Common Stock (or Other Securities) for the securities or other
property deliverable upon such reorganization, reclassification,
recapitalization, consolidation, merger, transfer, dissolution, liquidation or
winding-up. Such notice shall be mailed at least 20 days prior to the date
therein specified but in no event earlier than the public announcement of such
proposed transaction or event.

                9. REGISTRATION OF COMMON STOCK. If any shares of Common Stock
required to be reserved for purposes of exercise of this Warrant require
registration with or approval of any governmental authority under any federal or
state law (other than the Securities Act) before such shares may be issued upon
exercise, the Company shall, at its expense and as expeditiously as possible,
use its best efforts to cause such shares to be duly registered or approved, as
the case may be. At any such time as Common Stock is listed on any national
securities exchange or trade market, the Company shall, at its expense, obtain
promptly and maintain the approval for listing on each such exchange or trade
market, upon official notice of issuance, the shares of Common Stock issuable
upon exercise of the then outstanding Warrants and maintain the listing of such
shares after their issuance; and the Company shall also list on such national
securities exchange or trade market, shall register under the Exchange Act and
shall maintain such listing of, any Other Securities that at any time are
issuable upon

                                      -16-
<PAGE>   17

exercise of the Warrants, if and at the time that any securities of the same
class shall be listed on such national securities exchange or trade market by
the Company.

                10. RESERVATION OF STOCK, ETC. The Company shall at all times
reserve and keep available, solely for issuance and delivery upon exercise of
the Warrants, 150% of the number of shares of Common Stock (or Other Securities)
from time to time issuable upon exercise of all Warrants at the time outstanding
and otherwise in accordance with the terms of the Purchase Agreement. All shares
of Common Stock (or Other Securities) issuable upon exercise of any Warrants
shall be duly authorized and, when issued upon such exercise, shall be validly
issued and, in the case of shares, fully paid and nonassessable with no
liability on the part of the holders thereof, and, in the case of all
securities, shall be free from all taxes, liens, security interests,
encumbrances, preemptive rights and charges. The transfer agent for the Common
Stock, which may be the Company (the "Transfer Agent"), and every subsequent
Transfer Agent for any shares of the Company's capital stock issuable upon the
exercise of any of the purchase rights represented by this Warrant, are hereby
irrevocably authorized and directed at all times until the Expiration Date to
reserve such number of authorized and unissued shares as shall be requisite for
such purpose. The Company shall keep copies of this Warrant on file with the
Transfer Agent for the Common Stock and with every subsequent Transfer Agent for
any shares of the Company's capital stock issuable upon the exercise of the
rights of purchase represented by this Warrant. The Company shall supply such
Transfer Agent with duly executed stock certificates for such purpose. All
Warrant Certificates surrendered upon the exercise of the rights thereby
evidenced shall be canceled, and such canceled Warrants shall constitute
sufficient evidence of the number of shares of stock which have been issued upon
the exercise of such Warrants. Subsequent to the Expiration Date, no shares of
stock need be reserved in respect of any unexercised Warrant.

                11. REGISTRATION AND TRANSFER OF WARRANTS, ETC.

                11.1. Warrant Register; Ownership of Warrants. Each Warrant
issued by the Company shall be numbered and shall be registered in a warrant
register (the "Warrant Register") as it is issued and transferred, which Warrant
Register shall be maintained by the Company at its principal office or, at the
Company's election and expense, by a Warrant Agent or the Company's transfer
agent. The Company shall be entitled to treat the registered Holder of any
Warrant on the Warrant Register as the owner in fact thereof for all purposes
and shall not be bound to recognize any equitable or other claim to or interest
in such Warrant on the part of any other Person, and shall not be affected by
any notice to the contrary, except that, if and when any Warrant is properly
assigned in blank, the Company may (but shall not be obligated to) treat the
bearer thereof as the owner of such Warrant for all purposes. A Warrant, if
properly assigned, may be exercised by a new holder without a new Warrant first
having been issued.

                11.2. Transfer of Warrants. This Warrant and all rights
hereunder are transferable in whole or in part, without charge to the Holder
hereof, upon surrender of this Warrant with a properly executed Form of
Assignment attached hereto as Exhibit B at the principal office of the Company
together with an opinion of counsel, in generally

                                      -17-
<PAGE>   18

acceptable form, to the effect that such Warrant may be transferred pursuant to
an exemption from registration under the Securities Act of 1933 (or such other
office or agency of the Company as it may in writing designate to the Holder).
Upon any partial transfer, the Company shall at its expense issue and deliver to
the Holder a new Warrant of like tenor, in the name of the Holder, which shall
be exercisable for such number of shares of Common Stock with respect to which
rights under this Warrant were not so transferred and to the transferee a new
Warrant of like tenor, in the name of the transferee, which shall be exercisable
for such number of shares of Common Stock with respect to which rights under
this Warrant were so transferred.

                11.3. Replacement of Warrants. On receipt by the Company of
evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Warrant and, in the case of any such loss, theft or
destruction of this Warrant, on delivery of an indemnity agreement reasonably
satisfactory in form and amount to the Company or, in the case of any such
mutilation, on surrender of such Warrant to the Company at its principal office
and cancellation thereof, the Company at its expense shall execute and deliver,
in lieu thereof, a new Warrant of like tenor.

                11.4. Adjustments To Purchase Price and Number of Shares.
Notwithstanding any adjustment in the Purchase Price or in the number or kind of
shares of Common Stock purchasable upon exercise of this Warrant, any Warrant
theretofore or thereafter issued may continue to express the same number and
kind of shares of Common Stock as are stated in this Warrant, as initially
issued.

                11.5. Fractional Shares. Notwithstanding any adjustment pursuant
to Section 3 in the number of shares of Common Stock covered by this Warrant or
any other provision of this Warrant, the Company shall not be required to issue
fractions of shares upon exercise of this Warrant or to distribute certificates
which evidence fractional shares. In lieu of fractional shares, the Company
shall make payment to the Holder, at the time of exercise of this Warrant as
herein provided, in an amount in cash equal to such fraction multiplied by the
Current Market Price of a share of Common Stock on the date of Warrant exercise.

                12. REMEDIES; SPECIFIC PERFORMANCE. The Company stipulates that
there would be no adequate remedy at law to the Holder of this Warrant in the
event of any default or threatened default by the Company in the performance of
or compliance with any of the terms of this Warrant and accordingly, the Company
agrees that, in addition to any other remedy to which the Holder may be entitled
at law or in equity, the Holder shall be entitled to seek to compel specific
performance of the obligations of the Company under this Warrant, without the
posting of any bond, in accordance with the terms and conditions of this Warrant
in any court of the United States or any State thereof having jurisdiction, and
if any action should be brought in equity to enforce any of the provisions of
this Warrant, the Company shall not raise the defense that there is an adequate
remedy at law. Except as otherwise provided by law, a delay or omission by the
Holder hereof in exercising any right or remedy accruing upon any such breach
shall not impair the right or remedy or constitute a waiver of or

                                      -18-
<PAGE>   19

acquiescence in any such breach. No remedy shall be exclusive of any other
remedy. All available remedies shall be cumulative.

                13. NO RIGHTS OR LIABILITIES AS SHAREHOLDER. Nothing contained
in this Warrant shall be construed as conferring upon the Holder hereof any
rights as a stockholder of the Company or as imposing any obligation on the
Holder to purchase any securities or as imposing any liabilities on the Holder
as a stockholder of the Company, whether such obligation or liabilities are
asserted by the Company or by creditors of the Company.

                14. NOTICES. Any notices, consents, waivers or other
communications required or permitted to be given hereunder must be in writing
and will be deemed to have been delivered (i) upon receipt, when delivered
personally; (ii) upon receipt, when sent by facsimile, (iii) three days after
being sent by U.S. certified mail, return receipt requested, or (iv) one
Business Day after deposit with a nationally recognized overnight delivery
service, in each case properly addressed to the party to receive the same. The
addresses and facsimile numbers for such communications shall be:

                If to the Company:

                      NTN Communications, Inc.
                      The Campus
                      5966 LaPlace Court
                      Carlsbad, California  92008
                      Telephone:  (760) 438-7400
                      Facsimile:   (760) 930-1187
                      Attn:  Stanley B. Kinsey

                If to a Holder, to its address and facsimile number on the
register maintained by the Company. Each party shall provide five days' prior
written notice to the other party of any change in address or facsimile number.
Notwithstanding the foregoing, the exercise of any Warrant shall be effective in
the manner provided in Section 2.

                15. AMENDMENTS. This Warrant and any term hereof may not be
amended, modified, supplemented or terminated, and waivers or consents to
departures from the provisions hereof may not be given, except by written
instrument duly executed by the party against which enforcement of such
amendment, modification, supplement, termination or consent to departure is
sought.

                16. DESCRIPTIVE HEADINGS, ETC. The headings in this Warrant are
for convenience of reference only and shall not limit or otherwise affect the
meaning of terms contained herein. Unless the context of this Warrant otherwise
requires: (1) words of any gender shall be deemed to include each other gender;
(2) words using the singular or plural number shall also include the plural or
singular number, respectively; (3) the words "hereof", "herein" and "hereunder"
and words of similar import when used

                                      -19-
<PAGE>   20

in this Warrant shall refer to this Warrant as a whole and not to any particular
provision of this Warrant, and Section and paragraph references are to the
Sections and paragraphs of this Warrant unless otherwise specified; (4) the word
"including" and words of similar import when used in this Warrant shall mean
"including, without limitation," unless otherwise specified; (5) "or" is not
exclusive; and (6) provisions apply to successive events and transactions.

                17. GOVERNING LAW. This Warrant shall be governed by, and
construed in accordance with, the laws of the State of New York (without giving
effect to the conflict of laws principles thereof).

                18. JUDICIAL PROCEEDINGS. Any legal action, suit or proceeding
brought against the Company with respect to this Warrant may be brought in any
federal court in the District of Delaware or any state court located in New
Castle County, State of Delaware, and by execution and delivery of this Warrant,
the Company hereby irrevocably and unconditionally waives any claim (by way of
motion, as a defense or otherwise) of improper venue, that it is not subject
personally to the jurisdiction of such court, that such courts are an
inconvenient forum or that this Warrant or the subject matter may not be
enforced in or by such court. The Company hereby irrevocably and unconditionally
consents to the service of process of any of the aforementioned courts in any
such action, suit or proceeding by the mailing of copies thereof by registered
or certified mail, postage prepaid, at its address set forth or provided for in
Section 14, such service to become effective 10 days after such mailing. Nothing
herein contained shall be deemed to affect the right of any party to serve
process in any manner permitted by law or commence legal proceedings or
otherwise proceed against any other party in any other jurisdiction to enforce
judgments obtained in any action, suit or proceeding brought pursuant to this
Section. The Company irrevocably submits to the exclusive jurisdiction of the
aforementioned courts in such action, suit or proceeding.

                19. REGISTRATION RIGHTS AGREEMENT. The shares of Common Stock
(and Other Securities) issuable upon exercise of this Warrant (or upon
conversion of any shares of Common Stock issued upon such exercise) shall
constitute Registrable Securities (as such term is defined in the Registration
Rights Agreement). Each holder of this Warrant shall be entitled to all of the
benefits afforded to a holder of any such Registrable Securities under the
Registration Rights Agreement and such holder, by its acceptance of this
Warrant, agrees to be bound by and to comply with the terms and conditions of
the Registration Rights Agreement applicable to such holder as a holder of such
Registrable Securities.

                                      -20-
<PAGE>   21

                20. LIMITATION ON EXERCISE. Notwithstanding any provision to the
contrary contained herein, in no event shall the Holder be entitled to exercise
this Warrant, nor will the Company recognize such exercise, such that upon
giving effect to such exercise, the aggregate number of shares of Common Stock
then beneficially owned by the Holder and its "affiliates" as defined in Rule
144 of the Act would exceed 4.99% of the total issued and outstanding shares of
the Common Stock following such exercise; provided, however, that Holder may
elect to waive this restriction upon not less than sixty-one (61) days prior
written notice to the Company. For purposes of this Section, beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange
Act. For purposes of this Section 20, the Company shall not be held liable under
the penalty provisions of Section 2.6 as long as the Company acts in good faith
in its non-recognition of such exercise.

                                            NTN COMMUNICATIONS, INC.
                                               By:
                                               ---------------------------------
                                               Name:
                                               Title:

                                      -21-
<PAGE>   22

                                    [FORM OF]
                           ELECTION TO PURCHASE SHARES
                         AND TRANSFER AGENT INSTRUCTIONS

                The undersigned hereby irrevocably elects to exercise the
Warrant to purchase ____ shares of Common Stock, par value $.005 per share
("Common Stock"), of NTN COMMUNICATIONS, INC. (the "Company") and hereby [makes
payment of $________ in consideration therefor] [or] [makes payment in
consideration therefor by reduction pursuant to Section 2.1(b)(ii) of the
Warrant of the number of shares of Common Stock otherwise issuable to the Holder
upon Warrant exercise by ______ shares] [or] [makes payment in consideration
therefor by delivery of the following Common Stock Certificates of the Company
pursuant to Section 2.1(b)(iii) of the Warrant, certificates of which are
attached hereto for cancellation _______ [list certificates by number and
amount]]. The undersigned hereby requests that certificates for such shares be
issued and delivered as follows:

ISSUE TO:
         -----------------------------------------------------------------------
                                     (NAME)

--------------------------------------------------------------------------------
                          (ADDRESS, INCLUDING ZIP CODE)

--------------------------------------------------------------------------------
                  (SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER)

DELIVER TO:
           ---------------------------------------------------------------------
                                     (NAME)

--------------------------------------------------------------------------------
                          (ADDRESS, INCLUDING ZIP CODE)

                If the number of shares of Common Stock purchased hereby is less
than the number of shares of Common Stock covered by the Warrant, the
undersigned requests that a new Warrant representing the number of shares of
Common Stock not so purchased be issued and delivered as follows:

ISSUE TO:
         -----------------------------------------------------------------------
                                (NAME OF HOLDER)

--------------------------------------------------------------------------------
                          (ADDRESS, INCLUDING ZIP CODE)

DELIVER TO:
           ---------------------------------------------------------------------
                                    (NAME OF HOLDER)

--------------------------------------------------------------------------------
                          (ADDRESS, INCLUDING ZIP CODE)

Dated:                                      [NAME OF HOLDER]
      ---------------------------

                                            By
                                               ---------------------------------
                                               Name:
                                               Title:

<PAGE>   23

        __________________, as transfer agent and registrar of the Common Stock,
is hereby authorized and directed to issue the above number of shares of Common
Stock in the name of the above referenced entity or person and to deliver the
certificates representing such shares using an overnight delivery service.

                                            NTN COMMUNICATIONS, INC.

                                            By:
                                               ---------------------------------
                                               Name:
                                               Title:

<PAGE>   24

                                                   EXHIBIT B to
                                                   Common Stock Purchase Warrant

                              [FORM OF] ASSIGNMENT

                FOR VALUE RECEIVED, the undersigned hereby sells, assigns, and
transfers unto the Assignee named below all of the rights of the undersigned to
purchase Common Stock, par value $.005 per share ("Common Stock") of NTN
COMMUNICATIONS, INC. represented by the Warrant, with respect to the number of
shares of Common Stock set forth below:

<TABLE>
<CAPTION>
Name of Assignee                     Address                    No. of Shares
----------------                     -------                    -------------
<S>                                  <C>                        <C>

</TABLE>

and does hereby irrevocably constitute and appoint ________ as Attorney to make
such transfer on the books of NTN COMMUNICATIONS, INC. maintained for that
purpose, with full power of substitution in the premises.

Dated:                                      [NAME OF HOLDER]
      ---------------------------

                                            By
                                               ---------------------------------
                                               Name:
                                               Title:STOCK OPTION AGREEMENT

     THIS STOCK OPTION AGREEMENT is made and entered into as of December 10,
2000 (the "Agreement") by and between Shire Pharmaceuticals Group Plc, a company
registered in England under registry number 2883758 ("Shire"), and BioChem
Pharma Inc., a corporation incorporated under the laws of Canada ("BioChem"),
with respect to the following facts:

                                   WITNESSETH:

     A. Concurrently with the execution and delivery of this Agreement, Shire,
BioChem and 3829341 Canada Inc., a corporation incorporated under the laws of
Canada and an indirect wholly-owned subsidiary of Shire ("Exchangeco"), are
entering into a merger agreement (the "Merger Agreement"), which provides that,
among other things, upon the terms and subject to the conditions thereof, Shire
and BioChem will enter into a business combination transaction (the
"Arrangement").

     B. As a condition to Shire's willingness to enter into the Merger
Agreement, Shire has requested that BioChem agree, and BioChem has so agreed, to
grant to Shire an option to acquire BioChem Common Shares ("BioChem Shares"),
upon the terms and subject to the conditions set forth herein.

     C. Capitalized terms used and not otherwise defined herein that are defined
in the Merger Agreement shall have the respective meanings ascribed thereto in
the Merger Agreement.

     In consideration of the foregoing and the respective representations,
warranties and covenants set forth in this Agreement, and intending to be
legally bound hereby and thereby, the parties agree hereto as follows:

     1. Grant of Option.

     (a) Subject to the terms and conditions set forth herein, including receipt
of all regulatory approvals to the granting of the Option (including approvals,
as the case may be, of the TSE (collectively, the "Stock Exchange")), BioChem
hereby grants to Shire an irrevocable option (the "Option") to acquire up to
19.9% of the outstanding BioChem Shares as of December 8, 2000 (on an undiluted
basis) (the "Option Shares"), in the manner set forth below at a price (the
"Exercise Price") of US$37.00 per Option Share, payable in cash.

     (b) In the event Shire receives official notice that all regulatory
approvals necessary in respect of the granting of the Option, including approval
of the relevant Stock Exchange, will not be issued or granted, the Option and
this Agreement

<PAGE>
                                      -2-

shall be, and shall be deemed to be, one stock appreciation right ("SAR") with
respect to the Option Shares. At the request and upon notice by Shire at any
time during the period during which the Option is exercisable, BioChem (or any
successor entity thereof) shall purchase from Shire the SAR, at a price equal to
the difference between the "Market/Tender Offer Price" for BioChem Shares as of
the date Shire gives notice of its intent to exercise its rights under this
Section and the Exercise Price, multiplied by the number of BioChem Shares
purchasable pursuant to the Option. For purposes of this Agreement,
"Market/Tender Offer Price" means the higher of (A) the highest price per share
offered as of such date pursuant to any Acquisition Proposal which was made
prior to such date and not terminated or withdrawn as of such date and (B) the
highest closing sale price of BioChem Shares on the Nasdaq during the twenty
(20) trading days ending on the trading day immediately preceding such date. For
purposes of determining the highest price offered pursuant to any Acquisition
Proposal which involves consideration other than cash, the value of such
consideration shall be equal to the higher of (x) if securities of the proponent
of the same class as such consideration are traded on any national securities
exchange or by any registered securities association, a value based on the
closing sale price for such securities on their principal trading market on such
date and (y) the value ascribed to such consideration by the proponent of such
Acquisition Proposal, or if no such value is ascribed, a value determined in
good faith by the board of directors of BioChem.

     2. Exercise of Option; Maximum Proceeds.

     (a) The Option may be exercised by Shire, in whole or in part, at any time
and from time to time, immediately upon the occurrence of any event under
Section 7.2 of the Merger Agreement requiring BioChem to pay to Shire the amount
specified therein (the "Exercise Event"). In the event Shire wishes to exercise
the Option, Shire shall deliver to BioChem a written notice (each an "Exercise
Notice") specifying the total number of Option Shares it wishes to acquire and
pay the Exercise Price by certified cheque or wire transfer. Each closing of a
purchase of Option Shares (a "Closing") shall occur on a date and at a time
prior to the expiration of the Option designated by Shire in an Exercise Notice
delivered at least two Business Days prior to the date of such Closing, which
Closing shall be held at the offices of Stikeman Elliott, 1155 Rene-Levesque
Blvd. West, 40th Floor, Montreal (Quebec).

     (b) The Option shall expire upon the earliest to occur of (i) the Effective
Date, or (ii) the termination of the Merger Agreement pursuant to Article VII
thereof (other than a termination in connection with which Shire is or could in
time become entitled to any payments as specified in Section 7.2 thereof), or
(iii) 180 days after the date on which the Merger Agreement is terminated and
Shire has become entitled to a payment as specified in Section 7.2 thereof;
provided, however, that if the Option cannot be exercised by reason of any
applicable Laws, or because any applicable waiting period

<PAGE>
                                      -3-

related to issuance of the Option Shares under any applicable Laws shall not
have expired or been terminated, then the Option shall not terminate until the
tenth Business Day after such impediment to exercise shall have been removed or
shall have become final and not subject to appeal.

     (c) If Shire receives an amount pursuant to Section 7.2 of the Merger
Agreement which, when aggregated with gross proceeds received by Shire in
connection with any sales or other dispositions of Option Shares, less
reasonable and customary commissions paid in connection with such sales or
dispositions and any dividends received by Shire declared on Option Shares,
exceeds the sum of (x) US$120,000,000 plus (y) the Exercise Price multiplied by
the number of BioChem Shares purchased by Shire pursuant to the Option, then all
gross proceeds to Shire in excess of such sum shall be remitted by Shire to
BioChem or deducted from the payment to be made by BioChem pursuant to Section 1
(b) hereof.

     3. Conditions to Closing.

     The obligation of BioChem to issue Option Shares to Shire hereunder is
subject to the conditions that (a) all filings and declarations required to be
made, all authorizations, consents, orders and approvals required to be obtained
in connection with the grant of the Option and the issue of the Option Shares
(including the approval of the relevant Stock Exchange), and all waiting periods
required to expire or be terminated, pursuant to a requirement of any
Governmental Entity or applicable Law (including, without limitation the HSR Act
or the CA, as the case may be) shall have been made or obtained or shall have
expired or been terminated, in each case in connection with the exercise of the
Option hereunder; and (b) no preliminary or permanent injunction or other order
by any court of competent jurisdiction (or similar order from any Canadian, US
or UK securities authority) prohibiting or otherwise restraining such issuance
shall be in effect. It is understood and agreed that at any time during which
the Option is exercisable, the parties will use their respective commercial
reasonable efforts to satisfy all conditions to Closing, so that a Closing may
take place as promptly as practicable, and in any event, prior to consummation
of a tender or exchange offer or take-over bid for shares of BioChem capital
stock.

     4. Closing.

     At each Closing, (a) BioChem shall deliver to Shire a single certificate in
definitive form representing the number of BioChem Shares designated by Shire in
its Exercise Notice, such certificate to be registered in the name of Shire and
to bear the legend set forth in Section 10 hereof, against delivery of (b)
payment by Shire to BioChem of the aggregate purchase price for the BioChem
Shares so designated and being purchased by delivery of a certified cheque, bank
draft or wire transfer.

<PAGE>
                                      -4-

     5. Representations and Warranties of BioChem.

     BioChem represents and warrants to Shire that: (a) BioChem is a corporation
duly incorporated, validly existing and in good standing under the laws of
Canada and has full corporate power and authority to execute and deliver this
Agreement and to carry out its obligations hereunder; (b) the execution and
delivery of this Agreement by BioChem and consummation by BioChem of the
transactions contemplated hereby have been duly and validly authorized by all
necessary corporate action on the part of BioChem, and no other corporate
proceedings on the part of BioChem are necessary to authorize this Agreement or
any of the transactions contemplated hereby; (c) this Agreement has been duly
and validly executed and delivered by BioChem, constitutes a legal, valid and
binding obligation of BioChem and, assuming this Agreement constitutes a legal,
valid and binding obligation of Shire, is enforceable against BioChem in
accordance with its terms, except as enforceability may be limited by bankruptcy
and other laws affecting the rights and remedies of creditors generally and
general principles of equity; (d) except for any filings required under the CA
and the approval of the relevant Stock Exchange, BioChem has taken (or will in a
timely manner take) all necessary corporate and other action to authorize and
reserve for issuance and to permit it to issue upon exercise of the Option, and
at all times from the date hereof until the termination of the Option will have
reserved for issuance, a sufficient number of unissued BioChem Shares for Shire
to exercise the Option in full upon payment to BioChem of the Exercise Price in
connection therewith and will take all necessary corporate or other action to
authorize and reserve for issuance all additional BioChem Shares or other
securities which may be issuable pursuant to Section 9 upon exercise of the
Option and payment of the Exercise Price, all of which, upon their issuance and
delivery in accordance with the terms of this Agreement, will be validly issued,
fully paid and nonassessable; (e) upon delivery of the BioChem Shares and any
other securities to Shire upon exercise of the Option and payment of the
Exercise Price, Shire will acquire such BioChem Shares or other securities free
and clear of all material claims, liens, charges, encumbrances and security
interests of any kind or nature whatsoever, excluding those imposed by Shire;
(f) the execution and delivery of this Agreement by BioChem do not, and the
performance of this Agreement by BioChem will not, (i) conflict with the
articles of incorporation or bylaws of BioChem, (ii) assuming that the consent
approvals, authorizations, permits, filings and notifications referred to in
subsection 5d) are obtained or made as applicable, violate any order applicable
to BioChem or any of its Subsidiaries or by which they or any of their property
is bound or affected, or (iii) result in any breach of or constitute a default
(or an event which with notice or lapse of time or both would become a default)
under, or give rise to any right of termination, amendment, acceleration or
cancellation of, or result in the creation of a lien or encumbrance on any of
the property or assets of BioChem or any of its Subsidiaries pursuant to, any
contract or agreement to which BioChem or any of its Subsidiaries is a party or
by which BioChem or any of its Subsidiaries or any of their property is bound or
affected, except, in the case of clauses (ii) and (iii) above, for violations,
conflicts,

<PAGE>
                                      -5-

breaches, defaults, rights of termination, amendment, acceleration or
cancellation, liens or encumbrances which would not, in the aggregate, have a
Material Adverse Effect on BioChem; and (g) except as described in Section
3.2(c) of the Merger Agreement, the execution and delivery of this Agreement by
BioChem does not, and the performance of this Agreement by BioChem will not,
require any consent, approval, authorization or permit of, or filing with, or
notification to, any Governmental Entity, except pursuant to the CA, the HSR
Act, the rules and regulations of the Stock Exchange, the Canadian Securities
Laws, the applicable US and UK securities laws or other applicable Regulatory
Laws, as the case may be.

     6. Representations and Warranties of Shire.

     Shire represents and warrants to BioChem that: (a) Shire is a corporation
duly incorporated and validly existing under the laws of England, and has full
corporate power and authority to execute and deliver this Agreement and to carry
out its obligations hereunder; (b) the execution and delivery of this Agreement
by Shire and the consummation by Shire of the transactions contemplated hereby
have been duly and validly authorized by all necessary corporate action on the
part of Shire and no other corporate proceedings on the part of Shire are
necessary to authorize this Agreement or any of the transactions contemplated
hereby; (c) this Agreement has been duly and validly executed and delivered by
Shire, constitutes a legal, valid and binding obligation of Shire and, assuming
this Agreement constitutes a legal, valid and binding obligation of BioChem, is
enforceable against Shire in accordance with its terms, except as enforceability
may be limited by bankruptcy and other laws affecting the rights and remedies of
creditors generally and general principles of equity; (d) the execution and
delivery of this Agreement by Shire do not, and the performance of this
Agreement by Shire will not, (i) conflict with certificate of incorporation or
bylaws of Shire, (ii) violate any order applicable to Shire or any of its
subsidiaries or by which they or any of their property is bound or affected, or
(iii) result in any breach of or constitute a default (or an event which with
notice or lapse of time or both would become a default) under, or give rise to
any right of termination, amendment, acceleration or cancellation of, or result
in the creation of a lien or encumbrance on any of the property or assets of
Shire or any of its Subsidiaries pursuant to, any contract or agreement to which
Shire or any of its Subsidiaries is a party or by which Shire or any of its
Subsidiaries or any of their property is bound or affected, except, in the case
of clauses (ii) and (iii) above, for violations, conflicts, breaches, defaults,
rights of termination, amendment, acceleration or cancellation, liens or
encumbrances which would not, in the aggregate, have a Material Adverse Effect
on Shire; (g) the execution and delivery of this Agreement by Shire does not,
and the performance of this Agreement by Shire will not, require any consent,
approval, authorization or permit of, or filing with or notification to, any
Governmental Entity, except pursuant to the HSR Act, the CA or other applicable
Regulatory Laws, as the case may be; and (h) any BioChem Shares acquired upon
exercise of the Option will

<PAGE>
                                      -6-

not be acquired by Shire with a view to the public distribution thereof and
Shire will not sell or otherwise dispose of such shares in violation of
applicable law or this Agreement.

     7. Registration Rights.

     (a) In the event that Shire desires to sell any of the Option Shares within
two years after the first exercise of the Option and requests in writing to
BioChem that BioChem register such Option Shares under the Securities Act or
qualify such Option Shares for resale under applicable Canadian securities laws,
unless in the opinion of counsel to BioChem (which opinion shall be reasonably
satisfactory to Shire and its counsel) such registration under the Securities
Act or qualification under applicable Canadian securities laws is not required
in order to lawfully sell and distribute such Option Shares in the manner
contemplated by Shire, BioChem shall cooperate with Shire and any underwriters
in registering or qualifying of such Option Shares for resale, including,
without limitation, promptly filing a registration statement and/or prospectus
which complies with the requirements of applicable U.S. federal and state
securities laws and/or Canadian federal, provincial and territorial securities
laws, as the case may be, and entering into and complying with an underwriting
agreement with such underwriters upon such terms and conditions as are
customarily contained in underwriting agreements with respect to secondary
distributions; (i) provided, however, that BioChem shall not be required to file
more than two registration statements which are declared effective and/or
prospectuses hereunder and shall be entitled to delay the filing or
effectiveness of any registration statement and/or prospectus for up to 120
consecutive days in any 12-month period if the offering would, in the judgment
of the Board of Directors of BioChem, require premature disclosure of any
material corporate development or otherwise materially interfere with or
materially adversely affect any pending or proposed offering of securities of
BioChem, acquisition or divestiture or any other material transaction involving
BioChem or any of its subsidiaries and (ii) provided, however, that BioChem
shall not be required, with respect to an underwritten secondary offering, to
file a registration statement or a prospectus upon obtention from an investment
banking firm of nationally recognized standing (the "Manager") of a certificate
stating that, in the good faith belief of the Manager, based on the then
prevailing market condition, it will not be able to sell the Option Shares at a
per share price equal to at least 80% of the per share average of the closing
sale prices of BioChem's Shares on the TSE or the Nasdaq. Shire agrees to use
its reasonable commercial efforts to cause, and to use its commercial efforts to
cause any underwriters of any sale or other disposition to cause, any sale or
other disposition pursuant to such registration statement and/or prospectus to
be effected on a widely distributed basis so that upon consummation thereof no
purchaser or transferee will own beneficially more than (3%) of the
then-outstanding BioChem Shares.

     (b) If Option Shares are registered or qualified pursuant to the provisions
of this Section 8, BioChem agrees (i) to furnish copies of the registration

<PAGE>
                                      -7-

statement and/or prospectus relating to the Option Shares covered thereby in
such numbers as Shire may from time to time reasonably request and (ii) if any
event shall occur as a result of which it becomes necessary to amend or
supplement any registration statement or prospectus, to prepare and file under
the applicable securities laws such amendments and supplements as may be
necessary to keep available for at least 120 days a prospectus covering the
Option Shares meeting the requirements of such securities laws, and to furnish
Shire with such numbers of copies of the registration statement and prospectus,
as amended or supplemented, as may reasonably be requested. BioChem shall bear
the cost of the registration or qualification, including but nor limited to, all
registration and filing fees, printing expenses, and fees and disbursements of
its counsel and accountants for BioChem, and Shire shall pay the fees and
disbursement s of its counsel and the underwriting fees and commissions
applicable to the Option Shares sold by Shire. BioChem shall indemnify and hold
harmless Shire, its affiliates and their respective officers and directors from
and against any and all losses, claims, damages, liabilities and expenses
arising out of or based upon any statements contained in or omissions or alleged
omissions from, each registration statement or prospectus (or any amendment
thereto) filed pursuant to this paragraph; provided, however, that this
provision shall not apply to any loss, liability, claim, damage or expense to
the extent it arises out of any untrue statement or omission made in reliance
upon and in conformity with written information furnished by BioChem by Shire,
its affiliates and its officers and other representatives expressly for use in
any registration statement or prospectus (or any amendment thereto) filed
pursuant to this paragraph. BioChem shall also indemnify and hold harmless each
underwriter and each person who controls any underwriter against any and all
losses, claims, damages, liabilities and expenses arising out of or based upon
any statement contained in or omissions or alleged omissions from, each
registration statement or prospectus (or any amendment thereto) filed pursuant
to this Section 8.

     9. Adjustment Upon Changes in Capitalization; Rights Plans.

     (a) If any change shall occur in the BioChem Shares by reason of stock
dividends, stock splits, reverse stock splits, mergers, amalgamations (other
than the Arrangement), recapitalizations, combinations, exchanges of shares and
the like, then (i) the type and number of shares or securities subject to the
Option and (ii) the Exercise Price shall be adjusted appropriately, and proper
provision shall be made in the agreements governing such transaction so that
Shire shall receive, upon exercise of the Option, the number and class of shares
or other securities or property that Shire would have received in respect of the
BioChem Shares if the Option had been exercised immediately prior to such change
or the record date therefor, as applicable.

     (b) (i) In the event that BioChem enters into an agreement (A) to
amalgamate with or merge into any Person, other than Shire or any Subsidiary of
Shire (each an "Excluded Person"), and BioChem is not the successor corporation
of such

<PAGE>
                                      -8-

amalgamation or merger, (B) to permit any Person, other than an Excluded Person,
to merge into BioChem and BioChem shall be the successor corporation, but, in
connection with such merger, the then outstanding BioChem Common Shares shall be
changed into or exchanged for stock or other securities of any other Person or
cash or any other property or the then outstanding BioChem Common Shares shall
after such merger represent less than 50% of the outstanding voting securities
of the merged or acquiring company, or (C) to sell or otherwise transfer all or
substantially all of its assets to any Person, then, and in each such case, the
agreement governing such transaction shall make proper provision so that, unless
earlier exercised by Shire, the Option shall, upon the consummation of any such
transaction and upon the terms and conditions set forth herein, be converted
into, or exchanged for, an option with identical terms appropriately adjusted to
acquire the number and class of shares or other securities or property that
Shire would have received in respect of BioChem Common Shares if the Option had
been exercised immediately prior to such amalgamation, merger, sale, or
transfer, on the record date therefor, as applicable, and make any other
necessary adjustments; provided, however, that if such a conversion or exchange
cannot, because of applicable Law be the same as the Option, such terms shall be
as similar as possible and in no event less advantageous to Shire than the
Option.

     (ii) In addition to any other restrictions or covenants, BioChem agrees
that it shall not enter or agree to enter into any transaction described in this
Section 9(b) unless the Acquiring Corporation (as hereinafter defined) and any
Person that controls the Acquiring Corporation assume in writing all the
obligations of BioChem hereunder and agree for the benefit of Shire to comply
with this Section 9.

     (iii) For purposes of this Section 9(b), the term "Acquiring Corporation"
shall mean (x) the successor Person of an amalgamation or merger with BioChem
(if other than BioChem), (y) BioChem in an amalgamation or merger in which
BioChem is the successor Person, and (z) the transferee of all or substantially
all of BioChem's assets.

     10. Restrictive Legends.

     Each certificate representing Option Shares issued to Shire hereunder shall
include a legend in substantially the following form:

     THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
     UNDER THE SECURITIES ACT OF 1933, OR QUALIFIED FOR DISTRIBUTION TO THE
     PUBLIC PURSUANT TO APPLICABLE CANADIAN SECURITIES LAWS OR UK SECURITIES
     LAWS, AND MAY BE REOFFERED OR SOLD ONLY IF SO REGISTERED OR QUALIFIED OR IF
     AN EXEMPTION FROM SUCH REGISTRATION(S) OR REQUIREMENT TO FILE A PROSPECTUS
     IS AVAILABLE. SUCH

<PAGE>
                                      -9-

     SECURITIES ARE ALSO SUBJECT TO ADDITIONAL RESTRICTIONS ON TRANSFER AS SET
     FORTH IN THE STOCK OPTION AGREEMENT, DATED AS OF DECEMBER 10, 2000, A COPY
     OF WHICH MAY BE OBTAINED FROM THE ISSUER.

     Certificates representing shares sold in a registered public offering
pursuant to Section 8 shall not be required to bear the legend set forth in this
Section 10.

     11. Listing and HSR and Regulatory Approvals

     BioChem, upon the request of Shire, shall promptly file an application to
list the BioChem Shares to be acquired upon exercise of the Option on the Stock
Exchange and shall use its reasonable commercial efforts to obtain approval of
such listings as soon as practicable. Promptly after a request by Shire, BioChem
shall file Notification and Report Forms under the CA with the Competition
Bureau and make all filings required under the HSR Act. BioChem shall use all
its best reasonable efforts to respond as promptly as practicable to any
inquiries received from the Competition Bureau or in response to filings under
the HSR Act for additional information or documentation.

     12. Waiver of Voting Rights.

     Shire agrees that it shall have no voting rights, and shall not exercise or
permit to be exercised any voting rights in any circumstances, in respect of the
Option or the Option Shares unless, until, and only to the extent that the
Option has been exercised and the Exercise Price has actually been paid to
BioChem.

     13. Binding Effect.

     This Agreement shall be binding upon and inure to the benefit of the
parties hereto and their respective successors and permitted assigns. This
Agreement is not intended to confer any rights or remedies upon any Person other
than the parties hereto. Any shares sold by a party in compliance with the
provisions of Section 8 hereof shall, upon consummation of such sale, be free of
the restrictions imposed with respect to such shares by this Agreement and any
transferee of such shares shall not be entitled the rights of the transferor
under this Agreement.

     14. Specific Performance.

     Each of the parties hereto recognizes and acknowledges that a breach by it
of any covenants or agreements contained in this Agreement will cause the other
party to sustain damages for which it would not have an adequate remedy at law
for money damages. Therefore, in the event of any such breach, the aggrieved
party shall be entitled to the remedy of specific performance of such covenants
and agreements and injunctive and

<PAGE>
                                      -10-

other equitable relief in addition to any other remedy to which it may be
entitled, at law or in equity.

     15. Entire Agreement.

     This Agreement and the Merger Agreement, including the exhibits and
schedules thereto and the documents and instruments referred to therein embody
the entire agreement and understanding of the parties hereto in respect of the
subject matter contained herein. There are no representations, promises,
warranties, covenants, or undertakings, other than those expressly set forth or
referred to herein and therein.

     16. Further Assurances.

     Each party will execute and deliver all such further documents and
instruments and take all such further action as may be necessary in order to
consummate the transactions contemplated hereby.

     17. Severability.

     In case any one or more of the provisions contained in this Agreement
should be finally determined to be invalid, illegal or unenforceable in any
respect against a party hereto, it shall be adjusted if possible to effect the
intent of the parties. In any event, the validity, legality and enforceability
of the remaining provisions contained herein shall not in any way be affected or
impaired thereby, and such invalidity, illegality or unenforceability shall only
apply as to such party in the specific jurisdiction where such final
determination shall have been made.

     18. Notices.

     All notices and other communications hereunder shall be in writing and
shall be delivered personally, by overnight courier or similar means or sent by
facsimile with written confirmation of receipt, to the parties at the addresses
specified below (or at such other address for a party as shall be specified by
like notice). Any such notice shall be effective upon receipt, if personally
delivered, or on the next business day following transmittal, if sent by
facsimile. Notices shall be delivered as follows:

<PAGE>
                                      -11-

         (a)      if to Shire, to:

                           Shire Pharmaceuticals Group Plc
                           East Anton Andover
                           Hampshire, England
                           England SP10 5RG

                           Fax: 012 64 334 658
                           Attention: Rolf Stahel
                           with copies to:

                           McCarthy Tetrault
                           1170 Peel Street
                           Montreal, Quebec
                           H3B 4S8

                           Fax: (514) 397-4235
                           Attention: Benjamin H. Silver

         (b)      if to BioChem to:

                           Biochem Pharma Inc.
                           275 Armand-Frappier Blvd
                           Laval, Quebec
                           Canada   H7V 4A7

                           Fax: (450) 978-7899
                           Attention:  Francesco Bellini

                           with a copy to:

                           Stikeman Elliott
                           1155 Rene-Levesque Blvd West
                           Suite 4000
                           Montreal, Quebec
                           H3B 3V2

                           Fax: (514) 397-3222
                           Attention:  Jean Marc Huot

<PAGE>
                                      -12-

     19. Governing Law.

     This Agreement shall be governed and construed in accordance with the laws
of the Province of Quebec and the federal laws of Canada applicable therein
(without giving effect to choice of law principles thereof).

     20. Counterparts.

     This Agreement may be executed in two or more counterparts, each of which
shall be deemed to be an original, but both of which together shall constitute
one and the same instrument.

     21. Expenses.

     Except as otherwise expressly provided herein or in the Merger Agreement,
all costs, and expenses incurred in connection with the transactions
contemplated by this Agreement shall be paid by the party incurring such
expenses.

     22. Amendments; Waiver.

     This Agreement may be amended, modified or supplemented only by written
agreement of the parties. The terms and conditions hereof may be waived only by
an instrument in writing signed by the party granting such waiver, but such
waiver or failure to insist upon strict compliance with a term or condition
shall not operate as a waiver or estoppel with respect to, any subsequent or
other failure.

     23. Assignment.

     Neither this Agreement nor the Option created hereunder nor any right,
interest or obligation hereunder shall be assigned by either party without the
prior written consent of the other, except that this Agreement shall be binding
upon and inure to the benefit of the parties hereto and their successors and
permitted assigns.

     24. Currency.

     Except as expressly set forth otherwise, all sums of money referred to in
this Agreement are expressed in lawful money of Canada.

<PAGE>
                                      -13-

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
signed by their respective duly authorized officers as of the date first above
written.

                         SHIRE PHARMACEUTICALS GROUP PLC

                         By: /s/ Rolf Stahel
                             ---------------------------------------------------
                         Name:   Rolf Stahel
                         Title:  Chief Executive Officer

                         BIOCHEM PHARMA INC.

                         By: /s/ Francesco Bellini
                             ---------------------------------------------------
                         Name:   Francesco Bellini
                         Title:  Chairman and Chief Executive Officer

                         By: /s/ Francois Lagault
                             ---------------------------------------------------
                         Name:   Francois Legault
                         Title:  Executive Vice-President
                                 Corporate Development and Investments

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00018-of-00352.parquet"}]]